Shareholder Update Letter

  • 15 January 2017

January 15, 2017


Happy New Year from ProLung!

2016 has been a spectacular year.

To achieve our research goals more rapidly, we assembled the most extensive team of clinical investigators of lung cancer in pulmonology.

This speeds the […]

Gregory C. Simon Meeting

  • 10 December 2016

Steven C. Eror, President and CEO, meets with Gregory C. Simon, White House Cancer Moonshot Task Force, Executive Director in the Office of the Vice President.

ProLung Interviewed by National Healthcare Reporter

  • 2 November 2016



   ProLungDX seeks funds for cancer test; sees eventual IPO – CEO 
   Proprietary Intelligence


ProLungDX, a maker of lung cancer detection devices, is looking to raise USD 5.25m from high net worth investors for US […]

University of Liverpool Lung Cancer Research

  • 3 June 2016

Lung cancer survival rate increases by 73% if caught early
A major lung cancer screening trial, conducted by experts at the University of Liverpool, has found
that patients with a high risk of
developing lung cancer can be identified
with early stage disease […]

ProLungdx Announces Todd Morgan as Chairman of the Board

  • 19 May 2016

Salt Lake City, Utah, May 19, 2016 – Fresh Medical Laboratories, Inc, doing business as ProLungdx™, announced today that its board has appointed Todd Morgan as Chairman of the Board of Directors.  Mr. Morgan […]

ProLung study presented at IASLC 2015 Conference

  • 22 September 2015

September 22, 2015, Salt Lake City, Utah – A study comparing results from the ProLung EPN scan to the results of PET scans was presented at the 16th World Conference on Lung Cancer in Denver, […]

Dr. Jeffrey S. O’Driscoll joins Board of Directors

  • 21 August 2015

August 20, 2015, Salt Lake City Utah – The Board of Directors of the Company appointed Jeffrey S. O’Driscoll as a director of the Company.  Dr. O’Driscoll has practiced as an emergency physician since 1992.  He started […]

Leavitt Partners CEO McKeown joins ProLung Board of Directors

  • 2 July 2014

Salt Lake City, Utah (July 2, 2014) – “Rich McKeown brings a deep understanding of the healthcare industry as the chief executive of one of the nation’s most respected healthcare consulting firms,” said ProLung President […]

ProLung names Clark Campbell as Chairman of the Board

  • 12 September 2012

September 11, 2012, Salt Lake City, Utah—The medical technology company, ProLung, today announced the naming current board member Clark A. Campbell, Ph.D. as its new Chairman, replacing William A. Fresh, who continues as a Director. Campbell steps into this role as the company makes preparations to market the ProLung Test, a new tool in the early detection of lung cancer. Studies have shown that the test immediately and accurately identifies malignancy in patients who have been found to have an indeterminate lung mass. This can help solve the crucial problem of late detection, a major factor in lung cancer’s high mortality rate. “Dr. Campbell’s project management expertise will be invaluable as we embark on the final stages of preparing the ProLung Test for U.S. and international markets,” said Steven C. Eror, president and CEO of ProLung. “We’re fortunate to have him join us in our efforts to help give lung cancer patients a better chance for survival.”

Freshmedx announces name change to ProLung,TM underscoring its focus on the deadliest of cancers

  • 10 September 2012

September 11, 2012, Salt Lake City, Utah—Freshmedx today announced its intention to do business as ProLung, as it continues to commercialize the ProLung Test, a new tool in the early detection of lung cancer. According to company president Steven C. Eror, “The ProLung name expresses the hope this new test brings to the battle against the deadliest of all cancers. Studies have shown this new technology to be a major step forward in helping to solve the problems of late detection and difficult diagnosis, the main causes of lung cancer’s high mortality rate. ProLung reflects our commitment to promote lung health and improve outcomes for lung cancer patients.”

Freshmedx study published in the Journal of Thoracic Oncology, the official Journal of the International Association for the Study of Lung Cancer

  • 21 March 2012

March 20, 2012— Freshmedx today announced that its ground-breaking study on the use of computed bioconductance technology in detecting lung cancer will be published in April edition of the Journal of Thoracic Oncology. Freshmedx’s proprietary CB Test is a non- invasive adjunctive test that can evaluate patients with lesions suspicious for lung cancer and evaluate the likelihood that indeterminate lung lesions are malignant or benign. “We are pleased to have our clinical results published in the leading lung cancer journal,” said Steve Eror, president and chief executive officer of Freshmedx. “There is an increased need for this technology, especially given the recent National Lung Screening Trial (NLST) results and the adoption of Low-dose helical CT Screening (LDCT) programs.”

In the “Year of the Lung,” Utah Company Freshmedx Announces Breakthrough Lung Cancer Diagnostic

  • 18 February 2012

February 18, 2010—In celebration of World Cancer Day and the Year of the Lung, Freshmedx today announced that it has entered into multiple discussions for the international license of its Bioconductance Scanning Platform (BSP). The BSP is a medical device that can dramatically improve the accuracy of pre-surgical lung cancer diagnosis in a simple and painless 12-minute scan. Freshmedx is pursuing regulatory approvals in the US and has completed CE mark testing for European distribution. Cancer is projected to become the leading cause of death in 2010 according to the International Agency for Research on Cancer. Of all cancers, lung cancer is by far the most deadly. It results in more deaths than breast, prostate, colon, liver, kidney and melanoma cancers combined, yet it receives only one tenth the per-patient resources of other cancers.